Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33–RET fusions and BRAF V600E mutations

dc.contributor.authorBishop, Justin A.
dc.contributor.authorNakaguro, Masato
dc.contributor.authorWhaley, Rumeal D.
dc.contributor.authorOgura, Kanako
dc.contributor.authorImai, Hiroshi
dc.contributor.authorLaklouk, Israa
dc.contributor.authorFaquin, William C.
dc.contributor.authorSadow, Peter M.
dc.contributor.authorGagan, Jeffrey
dc.contributor.authorNagao, Toshitaka
dc.contributor.departmentPathology and Laboratory Medicine, School of Medicineen_US
dc.date.accessioned2023-03-14T11:30:04Z
dc.date.available2023-03-14T11:30:04Z
dc.date.issued2021-09
dc.description.abstractAims: Salivary gland intraductal carcinoma (IDC) is a complex ductal neoplasm surrounded by a layer of myoepithelial cells. Recent insights have shown that there are three different types: intercalated duct-like, with frequent NCOA4-RET fusions; apocrine, with salivary duct carcinoma-like mutations; and mixed intercalated duct-like/apocrine, with RET fusions, including TRIM27-RET. In addition, an oncocytic IDC has been described, but it remains unclear whether it represents a fourth variant or simply oncocytic metaplasia of another IDC type. Our aim was to more completely characterize oncocytic IDC. Methods and results: Six IDCs with oncocytic changes were retrieved from the authors' archives, from three men and three women ranging in age from 45 to 75 years (mean, 63 years). Five arose in the parotid gland, with one in an accessory parotid gland. Four patients with follow-up were free of disease after 1-23 months. Several immunostains (S100, mammaglobin, androgen receptor, and p63/p40) and molecular tools (RNA sequencing, RET fluorescence in-situ hybridisation, BRAF V600E VE1 immunohistochemistry, and Sanger sequencing) were applied. Histologically, the tumours were variably cystic with solid intracystic nodules often difficult to recognise as intraductal. In all, tumour ducts were positive for S100 and mammaglobin, negative for androgen receptor, and completely surrounded by myoepithelial cells positive for p63/p40. Molecular analysis revealed TRIM33-RET in two of six cases, NCOA4-RET in one of six cases, and BRAF V600E in two of six cases. One case had no identifiable alterations. Conclusions: Oncocytic IDC shares similarities with intercalated duct-like IDC. Although additional verification is needed, the oncocytic variant appears to be sufficiently unique to be now regarded as the fourth distinct subtype of IDC. Because of its indolent nature, oncocytic IDC should be distinguished from histological mimics.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationBishop JA, Nakaguro M, Whaley RD, et al. Oncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33-RET fusions and BRAF V600E mutations. Histopathology. 2021;79(3):338-346. doi:10.1111/his.14296en_US
dc.identifier.urihttps://hdl.handle.net/1805/31872
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1111/his.14296en_US
dc.relation.journalHistopathologyen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectIntraductal carcinomaen_US
dc.subjectSalivary gland neoplasmsen_US
dc.subjectTumor biomarkersen_US
dc.subjectDuctal carcinomaen_US
dc.subjectOxyphil cellsen_US
dc.titleOncocytic intraductal carcinoma of salivary glands: a distinct variant with TRIM33–RET fusions and BRAF V600E mutationsen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-1722416.pdf
Size:
3.85 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: